Endurity Pacemaker | Abbott
CARDIOVASCULAR
hamburger
Endurity

Shaping the Future

The Endurity™ pacemaker offers exceptional longevity in a small device size and a physiologic physician-preferred shape enabling a smaller incision and pocket size.

graphic showing the longevity, size, and warranty

Small

Designed for ease of implant, this 10 cc physician-preferred shape1 and size pacemaker can enable a smaller incision and pocket size.

Simplified

Easy access to a comprehensive suite of diagnostic data simplifies patient management and saves valuable time during routine, in-clinic, follow-up visits.4

Therapy Assurance

  • Reduce unnecessary RV pacing with beat-by-beat ventricular support to optimize patient safety and support intrinsic heart rhythm; Ventricular Intrinsic Preference (VIP™) has been shown to reduce RV pacing and heart-failure hospitalization.5
  • Ensure patient safety while managing changing patient thresholds; verify capture on a beat-by-beat basis, keeping output as low as possible to maximize pacemaker longevity.

Premium Features

Physician-Preferred Size and Shape

Physician-preferred size and physiologic shape minimize pocket size.

Autocapture™ Pacing System

This feature offers the maximum in threshold adaptability and patient safety with ventricular Beat-by-Beat™ capture confirmation.6 The AutoCapture pacing system automatically delivers a 5,0 V backup safety pulse when noncapture is detected, and it may be programmed to either a bipolar or unipolar configuration.

Programmable Real-time Electrogram (EGM) Waveform

Real-time electrogram (EGM) waveform, as well as the associated event markers that precede and follow a specific triggering event, can be programmed to automatically record up to 14 minutes of stored EGMs when encountering one or more programmable trigger options.

Specific Features for our Dual- and Single-Chamber Models

Dual-Chamber

STATE-OF-THE-ART FEATURES
  • Complete automaticity (atrial and ventricular)
  • Ventricular Intrinsic Preference (VIP™) technology
  • AF Suppression™ algorithm and SenseAbility™ technology—designed to deliver optimal therapy for patients at implant and throughout their lives
     
LONGEVITY
  • Outstanding longevity provides 9.4 years of service life,6 which is supported by an 8-year warranty*
  • 6-month ERI-EOL interval
     

Single-Chamber

STATE-OF-THE-ART FEATURES
  • Automaticity
  • Ventricular AutoCapture™ pacing system for ventricular implants
  • ACap™ Confirm, AF Suppression™ algorithm and AT/AF diagnostics for atrial implants, and SenseAbility™ technology—designed to deliver optimal therapy for patients at implant and throughout their lives
     
LONGEVITY
  • Outstanding longevity provides 14.4 years of service life,7 which is supported by an 8-year warranty*
  • 6-month ERI-EOL interval

Ordering Information

Endurity Single-Chamber Pacemaker
Order Number Dimensions (H x W x T, mm) Weight (g) Volume (cc) Connector
PM1160 41 x 50 x 6 19 9.7 (±0.5) IS-1

 

Endurity Dual-Chamber Pacemaker
Order Number Dimensions (H x W x T, mm) Weight (g) Volume (cc) Connector
PM2160 46 x 50 x 6 19 10.4 (±0.5) IS-1
Sign Up for Updates

*Terms and conditions apply; refer to the warranty for details.

References

  1. St. Jude Medical. Data on file, Report 60048640. Market Research Report: Pacemaker Size and Shape. 2012.
  2. Dual-chamber model; A,V = 2,5 V @ 0,4 ms; 600 ohms; 100% DDD pacing @ 60 bpm; AutoCapture™ Pacing System OFF; SEGMs ON (10 years). Single-chamber model; A,V = 2,5 V @ 0,4 ms; 600 ohms; 100% VVI pacing @ 60 bpm; AutoCapture™ Pacing System OFF; SEGMs ON (15 years).
  3. Single-chamber model; dual-chamber model warranty is 8 years; terms and conditions apply; refer to the warranty for details.
  4. St. Jude Medical data on file, Report 60033898. Enhanced Merlin Reports Human Factors Engineering Validation.
  5. Faulknier, B., & Richards, M. (2012, December). The association of the use of the ventricular intrinsic preference (VIP™) feature with heart failure hospitalization in pacemaker patients. Presented at the XV International Symposium on Progress in Clinical Pacing, Rome, Italy.
  6. Lau C & Sui C. Pacing technology: Advances in pacing threshold management.  浙江大学学报:B卷英文版 / Journal of Zhejiang University Science. 2010;11(8), 634-638.
  7. A,V = 2,5 V @ 0,4 ms; 500 ohms; 100% VVI pacing @ 60 bpm; AutoCapture™ Pacing System OFF; SEGMs ON.
Important Safety Information

IMPORTANT SAFETY INFORMATION

Rx Only

Endurity™ Dual- and Single-Chamber
Pacemaker System

Indications

Implantation is indicated in one or more of the following permanent conditions, or any combination of these symptoms: syncope, presyncope, fatigue, disorientation. Rate-Modulated Pacing is indicated for patients with chronotropic incompetence, and for those who would benefit from increased stimulation rates concurrent with physical activity. Dual-Chamber Pacing is indicated for those patients exhibiting: sick sinus syndrome; chronic, symptomatic second- and third-degree AV block; recurrent Adams-Stokes syndrome; symptomatic bilateral bundle branch block when tachyarrhythmia and other causes have been ruled out. Atrial Pacing is indicated for patients with sinus node dysfunction and normal AV and intraventricular conduction systems. Ventricular Pacing is indicated for patients with significant bradycardia and; normal sinus rhythm with only rare episodes of A-V block or sinus arrest, chronic atrial fibrillation, severe physical disability. AF Suppression algorithm stimulation is indicated for suppression of paroxysmal or persistent atrial fibrillation episodes in patients with one or more of the above pacing indications.

Contraindications

Single-chamber and dual-chamber pulse generators are contraindicated in patients with an implanted cardioverter-defibrillator. Rate-Adaptive Pacing may be inappropriate for patients who experience angina or other symptoms of myocardial dysfunction at higher sensor-driven rates. An appropriate Maximum Sensor Rate should be selected based on assessment of the highest stimulation rate tolerated by the patient. AF Suppression algorithm stimulation is not recommended in patients who cannot tolerate high atrial-rate stimulation. Dual-Chamber Pacing, though not contraindicated for patients with chronic atrial flutter, chronic atrial fibrillation or silent atria, may provide no benefit beyond that of single-chamber pacing in such patients. Single-Chamber Ventricular Demand Pacing is relatively contraindicated in patients who have demonstrated pacemaker syndrome, have retrograde VA conduction or suffer a drop in arterial blood pressure with the onset of ventricular pacing. Single-Chamber Atrial Pacing is relatively contraindicated in patients who have demonstrated compromise of AV conduction. add statement: For specific contraindications associated with individual modes, refer to the programmer's on-screen help.

Potential Adverse Events

The following are potential complications associated with the use of any pacing system: air embolism; body rejection phenomena; cardiac tamponade or perforation; hematoma, bleeding hematoma, seroma; formation of fibrotic tissue, local tissue reaction; inability to interrogate or program due to programmer or device malfunction; infection; erosion; interruption of desired pulse generator function due to electrical interference, either electromyogenic or electromagnetic; lead malfunction due to conductor fracture or insulation degradation; loss of capture or sensing due to lead dislodgement or reaction at the electrode/tissue interface; loss of desired pacing and/or sensing due to lead displacement, body reaction at electrode interface, or lead malfunction (fracture or damage to insulation); loss of normal device function due to battery failure or component malfunction; pacemaker migration or pocket erosion; pectoral muscle or diaphragmatic stimulation; phrenic nerve stimulation; pneumothorax/hemothorax; device migration and pocket erosion; endocarditis; excessive bleeding; induced atrial or ventricular arrhythmias; myocardial irritability; pericardial effusion; pericardial rub; pulmonary edema; rise in threshold and exit block; valve damage; death.

MAT-2117157 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.